The 12 closest competitors and alternatives to Caris Life Sciences, Inc. among health learning companies — ranked by similarity to what Caris Life Sciences, Inc. actually does, not by market-cap band.
Subscribe to see Caris Life Sciences, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
Caris Life Sciences, Inc. is a health learning company headquartered in Irving, United States. It is publicly listed (CAI) with a market capitalisation of $6.1B. Xcout tracks 46 named people at Caris Life Sciences, Inc., including Stephanie Thomas (Executive VP & Chief of Staff at Office of the CEO).
40 more named people on record for Caris Life Sciences, Inc., with roles, board committees and tenure — see the full roster →
Ranked by semantic similarity — how close each company is to Caris Life Sciences, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Healthcare
Inocras Inc. is a bioinformatics-led biotechnology company headquartered in San Diego, California. The firm utilizes whole genome data and proprietary artificial intelligence analytics to deliver curated genomic care.
Biotech
GENinCode Plc specializes in the creation and commercialization of advanced genetic tests designed to forecast potential health risks based on an individual's DNA. Operating in both the United Kingdom and internationally, their predictive technology empowers individuals and medical professionals alike with proactive health management and targeted intervention strategies. The company's sophisticated molecular diagnostics leverage a combination of clinical algorithms and artificial intelligence to deliver precise patient risk assessments, thereby anticipating the onset of various diseases. Among their specialized tests are: Cardio inCode: A patented genetic assay designed to guide individuals in cardiovascular prevention. Lipid inCode: A genetic diagnostic tool that analyzes seven specific genes associated with familial hypercholesterolemia. SUDD inCode: A genetic test to identify the underlying causes of sudden cardiac death and inherited heart conditions. Thrombo inCode: This test assesses 12 genetic variants linked to hereditary thrombophilia and the general risk of thrombosis (blood clots). Thrombo inCode Reproductive Health: Offering crucial insights into thrombophilia risks particularly relevant to prospective pregnancies. Established in 2018, GENinCode Plc maintains its headquarters in Oxford, United Kingdom.
Biotech
NeoGenomics, Inc. is a specialized clinical laboratory company headquartered in Fort Myers, Florida. It operates a network of CAP-accredited and CLIA-certified laboratories to provide comprehensive oncology testing and sample processing services.
Healthtech
Valius Health, Inc. provides comprehensive cancer diagnostic and tumor profiling services for patients and oncologists. The company analyzes tumor DNA, RNA, and proteins to identify actionable therapeutic targets and treatment options.
Healthcare
Innocras is a genomic analysis and cancer big data company founded in South Korea by physician-scientists from KAIST, maintaining research and corporate presence in both the United States and Korea. The company specializes in advanced cancer diagnostics and genomic technology to support precision oncology.
Biotechnology
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.
Healthtech
PathAI, Inc. is a healthcare technology company that develops artificial intelligence and machine-learning tools for digitizing and analyzing pathology images. It serves biopharmaceutical companies, research organizations, and pathology laboratories by supporting drug development, clinical trials, and diagnostic workflows.
Medical - Healthcare Information Services
Tempus AI, Inc. is an American health technology company founded in 2015 in Chicago, Illinois. The company builds a practical platform to gather and analyze clinical and molecular data, empowering physicians to make data-driven patient care decisions.
Biotech
Gene Solutions LLC provides AI-powered genetic testing and multi-dimensional genomics services focused on oncology and reproductive health. The company offers blood-based early cancer detection tests, tumor profiling, and minimal residual disease monitoring for patients and healthcare providers.
Medical - Diagnostics & Research
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
Life Sciences
CellCarta operates as a global contract research organization (CRO) providing specialized laboratory testing and biomarker services to support drug development and precision medicine. The company offers a wide range of services including immunology, proteomics, genomics, histopathology, and companion diagnostic development for pharmaceutical and biotechnology clients.
Biotech, Diagnostics
Novigenix is an immuno-transcriptomics and TechBio company that provides precision oncology solutions for biopharmaceutical companies and researchers. It offers LITOseek, an AI-powered liquid biopsy platform that analyzes gene activity in immune cells to support biomarker discovery, therapy development, and patient response monitoring.
Search any company we track to see its competitive set.
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Caris Life Sciences, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →